SGLT2抑制剂对2型糖尿病患者心血管保护作用研究的进展  

Research progress of cardiovascular protective effect of SGLT2 inhibitor on patients with type 2 diabetes mellitus

作　　者：汝子萱 丛丽[1] RU Zi-xuan;CONG Li(Department of Endocrinology and Metabolism,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150001,China)

机构地区：[1]哈尔滨医科大学附属第二医院内分泌与代谢病科,黑龙江哈尔滨150001

出　　处：《心血管康复医学杂志》2020年第3期392-396,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：心血管疾病(CVD)是2型糖尿病(T2DM)患者的首要死因。钠-葡萄糖转运体2(SGLT2)抑制剂是一种新近使用的降糖药,大量研究表明其对于T2DM患者的心血管具有保护作用。但其中涉及的机制尚未探明。在应用SGLT2抑制剂时,应利用其保护心血管作用的优势,也应警惕其不良反应。本文汇总了近年SGLT2抑制剂对T2DM患者心血管获益有关的临床研究,以期为T2DM合并CVD患者的治疗提供新思路。Cardiovascular diseases(CVDs)are the primary cause of death for patients with type 2 diabetes mellitus(T2DM).Sodium glucose cotransporter 2(SGLT2)inhibitor is a novel hypoglycemic agent,and many researches indicated that it possessed protective effect on cardiovascular system in T2DM patients.But the involved mechanisms are still not clear.In application of SGLT2 inhibitor,its adverse reactions should be alerted while making use of its advantage of protecting cardiovascular system.The present article summarized related researches about cardiovascular benefits of SGLT2 inhibitor for T2DM patients in recent years,aiming at providing new thinking for treatment of T2DM+CVD patients.

关 键 词：心血管疾病 糖尿病 2型 钠-葡萄糖转运体2 

分 类 号：R54[医药卫生—心血管疾病]